Table 1 Male, female, and cohort specific mortality according to age (sex and country adjusted), disease phenotype at diagnosis (age, sex, and country adjusted), and residence (age and sex adjusted).
| Male | Female | Entire cohort | Groupings entire cohort | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Dead | Exp | SMR (95%CI) | No | Dead | Exp | SMR (95%CI) | No | Dead | Exp | SMR (95%CI) | No | Dead | Exp | SMR (95%CI) | |
| Total | 183 | 21 | 11.8 | 1.79 (1.11–2.73) | 188 | 16 | 8.28 | 1.93 (1.10–3.14) | 371 | 37 | 21.5 | 1.85 (1.30–2.55) | ||||
| Age at diagnosis | ||||||||||||||||
| <40 y | ||||||||||||||||
| 10–19 | 25 | 1 | 0.22 | 4.51 (0.06–25.1) | 26 | 0 | 0.07 | 0 (–) | 51 | 1 | 0.29 | 3.39 (0.04–18.9) | 241 | 3 | 2.32 | 1.29 (0.26–3.78) |
| 20–29 | 58 | 1 | 0.65 | 1.53 (0.02–8.51) | 67 | 1 | 0.34 | 2.95 (0.04–16.4) | 125 | 2 | 0.99 | 2.01 (0.23–7.27) | ||||
| 30–39 | 28 | 0 | 0.50 | 0 (–) | 38 | 0 | 0.41 | 0 (–) | 66 | 0 | 0.91 | 0 (–) | ||||
| ⩾40 y | ||||||||||||||||
| 40–49 | 28 | 1 | 1.28 | 0.78 (0.01–4.34) | 21 | 2 | 0.53 | 3.80 (0.43–13.7) | 49 | 3 | 1.81 | 1.66 (0.33–4.85) | 117 | 33 | 16.6 | 1.99 (1.37–2.80) |
| 50–59 | 18 | 2 | 1.94 | 1.03 (0.12–3.71) | 15 | 1 | 0.90 | 1.11 (0.01–6.15) | 33 | 3 | 2.85 | 1.05 (0.09–39.8) | ||||
| 60–69 | 14 | 6 | 3.65 | 1.64 (0.60–3.58) | 8 | 3 | 1.10 | 2.72 (0.55–7.94) | 22 | 9 | 4.75 | 1.89 (0.86–3.59) | ||||
| 70–79 | 11 | 9 | 3.48 | 2.58 (1.18–4.91) | 11 | 7 | 3.36 | 2.08 (0.84–4.30) | 22 | 16 | 6.84 | 2.34 (1.34–3.80) | ||||
| 80–89 | 1 | 1 | 0.01 | 82.8 (1.08–461) | 2 | 2 | 1.56 | 1.28 (0.14–4.62) | 3 | 3 | 1.57 | 1.91 (0.38–5.57) | ||||
| Disease location at diagnosis | ||||||||||||||||
| Ileum | 26 | 6 | 3.68 | 1.63 (0.60–3.55) | 27 | 4 | 2.15 | 1.86 (0.50–4.77) | 53 | 3 | 2.41 | 1.24 (0.25–3.63) | ||||
| Colon | 73 | 13 | 5.83 | 2.23 (1.19–3.81) | 78 | 8 | 4.41 | 1.81 (0.78–3.57) | 151 | 21 | 10.2 | 2.05 (1.27–3.13) | ||||
| Ileocolon | 69 | 1 | 1.67 | 0.60 (0.01–3.33) | 65 | 2 | 0.74 | 2.69 (0.30–9.73) | 134 | 10 | 5.83 | 1.72 (0.82–3.16) | ||||
| Upper GI | 9 | 1 | 0.29 | 3.44 (0.04–19.1) | 11 | 1 | 0.13 | 7.75 (0.10–43.1) | 20 | 2 | 0.42 | 4.76 (0.54–17.2) | ||||
| Disease behaviour at diagnosis | ||||||||||||||||
| Inflammatory | 132 | 18 | 8.47 | 2.12 (1.26–3.36) | 132 | 10 | 4.24 | 2.36 (1.13–4.34) | 264 | 28 | 12.7 | 2.20 (1.46–3.18) | ||||
| Stricturing | 29 | 3 | 1.85 | 1.62 (0.33–4.74) | 28 | 3 | 2.52 | 1.19 (0.24–3.48) | 57 | 6 | 4.37 | 1.37 (0.50–2.99) | ||||
| Penetrating | 14 | 0 | 1.12 | 0 (–) | 16 | 2 | 0.64 | 3.10 (0.35–11.2) | 30 | 2 | 1.77 | 1.13 (0.13–4.08) | ||||
| Penetrating and stricturing | 2 | 0 | 0.02 | 0 (–) | 5 | 0 | 0.03 | 0 (–) | 7 | 0 | 0.05 | 0 (–) | ||||
| Country | ||||||||||||||||
| South | ||||||||||||||||
| Greece | 16 | 4 | 1.51 | 2.65 (0.71–6.78) | 5 | 0 | 0.02 | 0 (–) | 21 | 4 | 1.53 | 2.61 (0.70–6.67) | 130 | 12 | 7.76 | 1.55 (0.80–2.70) |
| Italy | 20 | 2 | 2.05 | 0.98 (0.11–3.53) | 22 | 2 | 1.43 | 1.39 (0.16–5.04) | 42 | 4 | 3.48 | 1.15 (0.31–2.94) | ||||
| Israel | 5 | 0 | 0.16 | 0 (–) | 16 | 1 | 0.33 | 3.02 (0.04–16.8) | 21 | 1 | 0.49 | 2.03 (0.03–11.3) | ||||
| Portugal | 5 | 0 | 0.40 | 0 (–) | 8 | 0 | 0.09 | 0 (–) | 13 | 0 | 0.49 | 0 (–) | ||||
| Spain | 25 | 3 | 1.72 | 1.74 (0.35–5.08) | 8 | 0 | 0.04 | 0 (–) | 33 | 3 | 1.77 | 1.70 (0.34–4.97) | ||||
| North | ||||||||||||||||
| Denmark | 20 | 5 | 2.01 | 2.49 (0.80–5.81) | 38 | 5 | 2.35 | 2.12 (0.68–4.96) | 58 | 10 | 4.36 | 2.29 (1.10–4.22) | 241 | 25 | 12.3 | 2.04 (1.32–3.01) |
| Norway | 56 | 5 | 2.85 | 1.75 (0.56–4.09) | 50 | 6 | 3.57 | 1.68 (0.61–3.65) | 106 | 11 | 6.43 | 1.71 (0.85–3.06) | ||||
| the Netherlands | 36 | 2 | 1.05 | 1.91 (0.21–6.91) | 41 | 2 | 0.43 | 4.64 (0.52–16.7) | 77 | 4 | 1.48 | 2.71 (0.73–6.94) | ||||
Thirteen patients with no known phenotype at diagnosis, of whom one female died due to pulmonary cause, were excluded from analysis in the age (<40 years and ⩾40 years), disease location, and behaviour at diagnosis categories.
No, number of patients; Exp, expected number of deaths; upper GI, upper gastrointestinal; SMR, standardised mortality ratio; 95% CI, 95% confidence interval.